Gamma-aminobutyric acid (GABA) treatment blocks inflammatory pathways and promotes survival and proliferation of pancreatic beta cells Gérald J. Prud homme, MD, FRCPC Keenan Research Centre for Biomedical Science, St. Michael s Hospital, Toronto. Department of Laboratory Medicine and Pathobiology, University of Toronto. Email: prudhommeg@smh.ca
Limitations of current therapies of diabetes Do not prevent or reverse type 1 diabetes (no cure). Minimal or no improvement in the survival of pancreatic beta cells (type 1 or 2). Do not induce replacement or regeneration of beta cells (type 1 or 2).
EFFECTS NEEDED TO CURE TYPE 1 DIABETES Stop the autoimmune (inflammatory) reaction that kills beta cells. Increase the resistance of beta cells to injury. Stimulate the regeneration of beta cells, or replace these cells. Research aspect: human beta cells are different from mouse. Drugs must work on human cells.
GLP-1 receptor agonists Effective in the treatment of type 2 diabetes Several drugs available or under investigation: exenatide [Byetta], liraglutide, dulaglutide, etc. Not effective in type 1 diabetes (lack antiinflammatory and regenerative capacity).
GABA Gamma-aminobutyric acid
GABA is an inhibitory neurotransmitter in the brain, but also present in the pancreas
GABA Brain: Major inhibitory neurotransmitter. Islets: Inhibits α cells, but stimulates β cells. Immune system: Inhibits lymphocytes and macrophages
GABA RECEPTORS Type A (GABA-A receptor): Fast acting ligand-gated chloride channel (many variants). Blocked by picrotoxin. Type B (GABA-B receptor): Slow acting G-protein coupled receptor. Blocked by saclofen. Neurons and islet cells: Express both receptors. Lymphocytes: Type A only.
GABA suppresses proliferation of human T cells (anti-cd3 antibody) P ro life r a tio n, % to th e c o n tro l c e lls 1 5 0 1 0 0 5 0 0 n o G A B A s a c lo fe n p ic r o to x in **** G A B A s a c lo fe n + G A B A p ic r o to x in + G A B A
Immunotherapeutic effects of GABA in T1D Strain/model Immune effects Disease course NOD(prediabetic) Th1 cells, IFN-γ prevented diabetes IL-12, Treg (insulitis ) NOD (diabetic) reversed transiently NOD-TCR8.3 CTL response prevented (insulitis ) CD1 mice IL-1, TNF-α reversed diabetes (low dose STZ, IL-12, IFN-γ (insulitis, β-cell diabetic) regeneration) Reviewed in: Prud homme et al. Autoimmunity reviews, 2015, 14:1048-56.
N F - B, % to th e n o n -tre a te d c e lls Inhibition of NF-kB in Mouse T cells (anti-cd3/cd28 stimulated) 1 5 0 1 0 0 5 0 **** **** **** 0 0 1 0 1 0 0 1 0 0 0 G A B A, M
N F - B, % to th e n o n -tre a te d c e lls GABA suppresses activation of NF-kB in human islets through GABA-A receptors 1 5 0 **** ** 1 0 0 5 0 0 n o n tr e a te d G A B A p ic r o to x in + G A B A s a c lo fe n + G A B A
GABA BLOCKS AUTOIMMUNE REACTION AGAINST BETA CELLS
GABA induces beta-cell regeneration
Mouse: GABA prevents β-cell death, stimulates β-cell proliferation, increases insulin secretion, and promotes β-cell regeneration. GABA exerts anti-inflammatory and immunosuppressive effects. Humans: Similar to mouse??
GABA stimulates insulin secretion
Human beta cells in culture
n u m b e r o f liv in g c e lls g a te d 1 0 n G A B GABA and Liraglutide (GLP-1R agonist) ameliorate P r e v e n tio n ohuman f c y to k in e beta-cell to x ic ity b y survival h ig h c o n c e n tr a tio n s o f G A B A a n d L ira g lu tid e in h u m a n is le ts a fte r 2 4 h. (24 h in vitro; additive effect) 2 0 0 0 c y t o k i n e t r e a t m e n t, h i g h 1 5 0 0 1 0 0 0 5 0 0 0 n t 1 0 0 u M G A B A 1 0 0 n M L ir a g lu tid e G A B A + L ir a g lu tid e C o m m e n t s : 1. c o m b in a tio n o f 1 0 0 M G A B A w ith 1 0 0 n M L ir a g lu tid e is m o
Non-treated islets Ki67 -red DAPI - green merge
Islets treated with 100 μm GABA Ki67 -red DAPI - green merge
K i6 7 + c e lls /is le t T h e e ffe c t o f G A B A o n th e p ro life r a tio n o f th e c e ll in h u m a n p a n c re a tic is le ts tr e a te d in v itr o fo r 1 9 h. 1.0 * 0.8 0.6 0.4 0.2 0.0 c o n tr o l G A B A 5 0 M G A B A 1 0 0 M Ki67 staining, See images below
Human islets transplanted into immunodeficient mice: GABA stimulates growth (regeneration) of beta cells
HYPOTHESES 1. Combined therapy with GABA and a DPP-4 inhibitor (DPP4-I) will improve protection of human beta cells against injury/apoptosis and induce regeneration. 2. A completely oral therapy will be effective, which is a major clinical advantage.
GABA AND GLP-1 WORK TOGETHER Our most recent data show that GABA and GLP-1 are more effective when administered together. Improved beta-cell survival and regeneration. Effective on human beta cells. Completely oral therapy protects against diabetes in experimental model.
Streptozotocin-induced diabetes (MDSD) A Non-Treated Insulin Glucagon DAPI Merge B β-cell mass (mg) 2.0 1.5 1.0 0.5 * ** *** * * GABA Insulin Glucagon DAPI Merge 0.0 Non-treated GABA Sitagliptin GABA+Sitagliptin Sitagliptin GABA+Sitagliptin Insulin Glucagon DAPI Merge C α-cell mass (mg) 0.8 0.6 0.4 0.2 ** ** *** P=0.058 Insulin Glucagon DAPI Merge 0.0 Figure 1 Non-treated GABA Sitagliptin GABA+Sitagliptin GABA AND DPP-4I collaborate to increase beta-cell mass. Red = insulin; green = glucagon; blue = DAPI. Treatment with combined drugs was superior to induce proliferation (Ki-67+ cells) and reduce apoptosis (Tunel assay); data not shown.
GABA and GABAergic drugs (agonistic) increase SIRT1 expression in INS-1 beta-cell line
GABA increases Klotho (alpha-klotho) In humans Klotho normally declines with age, and is abnormally low in diabetic patients (type 1 and 2). Klotho KO mice have multi-system disease and accelerated aging. Klotho has multiple protective effects on beta cells. Importantly, it inhibits NF-kB activation and exerts anti-apoptotic effect.
Structure of α-klotho ADAM10, ADAM17 BACE1 ADAM10, ADAM17, BACE1 N- KL1 KL2 -C Truncated soluble Klotho 65 kd Secreted Klotho (alternative splicing) 70 kd Soluble Klotho ~130 kd Membrane-bound klotho binds FGFR1 and facilitates binding of FGF23 to this receptor. Soluble klotho acts as a hormone with the receptors yet to be characterized. KL1 and KL2 domains structurally resemble glucosidase, but their enzymatic activity is questionable.
Binding partners of α-klotho FGF23, FGFR1 IGF-1 TGF-βRII Wnt family members? Cell proliferation Caspase-3 cleavage Apoptosis α-klotho shedding (activation of mtor) IGF-1 tyrosine kinase FOXO (antagonizes suppression by IGF-1) MnSOD expression Suppression of pancreatic cancer Prevents binding of TGFβ1 to TGF-βRII Inhibits EMT Inhibits accelerated senescence Suppresses tumor development Multiple effects mediated by nondescribed receptors
KLOTHO INHIBITS NF-κB ACTIVATION Buendia et al., Vitamins and Hormones, 2016, 101: 119-147
Schematic representation of the Klotho participating in intracellular signaling pathways. Klotho protein is involved in several intracellular signaling pathways that are essential for the regulation of many cellular processes, including aging and senescence. From: M. Sopjani et al. Klotho and Intracellular Signaling Current Molecular Medicine, 2015, Vol. 15, No. 1 33
c irc u la tin g k lo th o, p g /m l T h e le v e l o f c ir c u la tin g k lo th o is d e c re a s e d in d ia b e tic C 5 7 m ic e. It is r e s to r e d b y G A B A in d rin k in g w a te r. 1 5 0 0 1 0 0 0 5 0 0 0 c o n tr o l S T Z G A B A G A B A + S T Z
c irc u la tin g k lo th o, p g /m l T h e le v e l o f c ir c u la tin g k lo th o n e g a tiv e ly c o r r e la te s w ith th e le v e l o f b lo o d g lu c o s e 2 5 0 0 2 0 0 0 n o n -tre a te d G A B A -tre a te d 1 5 0 0 1 0 0 0 5 0 0 0 0 1 0 2 0 3 0 4 0 b lo o d g lu c o s e, m M Pearson r r 95% confidence interval R squared P value P (one-tailed) P value summary Significant? (alpha = 0.05) Number of XY Pairs blood glucose, mm vs. non-treated -0.6855-0.8771 to -0.3055 0.4699 0.0012 ** Yes 17 blood glucose, mm vs. GABA-treated -0.4399-0.7522 to 0.034 0.1935 0.0339 * Yes 18
K lo th o in s u p e rn a ta n t, p g /m l H ig h G lu c o s e in d u c e s re le a s e o f K lo th o b y c u ltu r e d h u m a n p a n c r e a tic is le ts. 1 0 0 0 8 0 0 6 0 0 4 0 0 2 0 0 0 c o n tr o l, N G G A B A -tr e a te d, N G c o n tr o l, H G G A B A -tr e a te d, H G
K lo th o in s u p e rn a ta n t, p g /m l C u ltu r e d h u m a n p a n c r e a tic is le ts r e le a s e K lo th o. T h e r e le a s e is n o ta b ly a c tiv a te d b y m u s c im o l a n d b a c lo fe n. 1 5 0 1 0 0 * * * * * * * P = 0.0 0 0 2 * P = 0.0 1 7 5 0 0 c o n tr o l m u s c im o l b a c lo fe n
liv e c e lls, % to c o n tr o l 2 0 0 S o lu b le -k lo th o in c re a s e s v ia b ility o f IN S -1 1 5 0 1 0 0 5 0 0 c o n tr o l k lo th o K D c o n tr o l+ k lo th o k lo th o K D + k lo th o Klotho knockdown Recombinant Klotho Cell viability
liv e c e lls, % to c o n tr o l A b ility o f G A B A to in c re a s e c e ll v ia b ility a n d to p ro te c t IN S -1 c e lls a g a in s t S T Z to x ic ity d e p e n d s o n -k lo th o e x p r e s s io n 2 0 0 n o k lo th o k n o c k d o w n k lo th o k n o c k d o w n 1 5 0 1 0 0 5 0 0 c o n tr o l G A B A S T Z G A B A + S T Z c o n tr o l G A B A S T Z G A B A + S T Z Klotho knockdown GABA Cell viability
Effects of Klotho/our preliminary data: 1. Klotho is expressed by rat (INS-1) and human pancreatic cells (donor islets). 2. Cultured islet cells actively release soluble Klotho. 3. The level of circulating Klotho in mouse serum is severely decreased during STZ-induced diabetes. GABA, but not Liraglutide, restores it. 4. Ability of GABA to increase the survival of beta cells under stress depends on the expression of Klotho.
GABA in food and beverages: It is a safe natural compound
GABA INCREASES GROWTH HORMONE
SUMMARY: GABA has key effects against diabetes (studies performed with human cells) 1) It prevents beta-cell injury and death. 2) It promotes the regeneration of beta cells. 3) It suppresses immune cells that cause autoimmunity and beta-cell loss. 4) It increases SIRT1 and Klotho, which suppress NF-κB activation and exert protective effects on beta cells. G. Prud homme, Q. Wang and colleagues (PNAS 2011; Transplantation 2013; Diabetes 2014; BBRC 2014; Frontiers Pharmacology 2015, 2017)
Future Goals 1. Clinical development of a new treatment for type 1 and 2 diabetes: GABA therapy, with or without GLP-1. 2. Determine whether GABA therapy has a role in the treatment of other chronic diseases.
Research Team Dr. Gérald Prud homme Dr. Qinghua Wang Dr. Tianru Jin Dr. Yelena Glinka Dr. Wenjuan Liu Ms. Merve Kurt Funding Juvenile Diabetes Research Foundation (JDRF) International